120 related articles for article (PubMed ID: 10874219)
1. Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression.
Sadzuka Y; Egawa Y; Sugiyama T; Sawanishi H; Miyamoto K; Sonobe T
Jpn J Cancer Res; 2000 Jun; 91(6):651-7. PubMed ID: 10874219
[TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia.
Sadzuka Y; Sugiyama T; Sawanishi H; Miyamoto K
Cancer Lett; 1999 Apr; 138(1-2):5-11. PubMed ID: 10378767
[TBL] [Abstract][Full Text] [Related]
3. Improvement of idarubicin induced antitumor activity and bone marrow suppression by theanine, a component of tea.
Sadzuka Y; Sugiyama T; Sonobe T
Cancer Lett; 2000 Oct; 158(2):119-24. PubMed ID: 10960760
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
5. Effects of xanthine derivatives on the influx and efflux of doxorubicin in P388 and DOX-resistant P388 leukemia cells.
Sadzuka Y; Egawa Y; Sawanishi H; Miyamoto K; Sonobe T
Toxicol Lett; 2002 Sep; 135(1-2):137-44. PubMed ID: 12243872
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
7. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.
Szmigielska-Kaplon A; Ciesielska E; Szmigiero L; Robak T
Eur J Haematol; 2002 Jun; 68(6):370-5. PubMed ID: 12225395
[TBL] [Abstract][Full Text] [Related]
8. Increased effects of MPDAX, a novel xanthine derivative, on antitumor activity of doxorubicin.
Sadzuka Y; Sugiyama T; Suzuki H; Sawanishi H; Miyamoto K
Toxicol Lett; 2004 May; 150(3):341-9. PubMed ID: 15110086
[TBL] [Abstract][Full Text] [Related]
9. Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice.
de Campos Nebel M; Larripa I; González-Cid M
Environ Mol Mutagen; 2002; 39(1):3-9. PubMed ID: 11813290
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
11. Externally triggered smart drug delivery system encapsulating idarubicin shows superior kinetics and enhances tumoral drug uptake and response.
Lu T; Haemmerich D; Liu H; Seynhaeve ALB; van Rhoon GC; Houtsmuller AB; Ten Hagen TLM
Theranostics; 2021; 11(12):5700-5712. PubMed ID: 33897876
[No Abstract] [Full Text] [Related]
12. Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Kroschinsky F; Schleyer E; Renner U; Schimming C; Schimmelpfennig C; Bornhäuser M; Illmer T; Trümper L; Ehninger G; Schaich M
Cancer Chemother Pharmacol; 2004 Jan; 53(1):61-7. PubMed ID: 12955471
[TBL] [Abstract][Full Text] [Related]
13. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.
Dos Santos N; Waterhouse D; Masin D; Tardi PG; Karlsson G; Edwards K; Bally MB
J Control Release; 2005 Jun; 105(1-2):89-105. PubMed ID: 15878792
[TBL] [Abstract][Full Text] [Related]
14. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Tolomeo M; Gancitano RA; Musso M; Porretto F; Perricone R; Abbadessa V; Cajozzo A
Cancer Chemother Pharmacol; 1996; 39(1-2):157-61. PubMed ID: 8995514
[TBL] [Abstract][Full Text] [Related]
16. 1-Methyl-3-propyl-7-butylxanthine, a novel biochemical modulator, enhances therapeutic efficacy of adriamycin.
Sadzuka Y; Iwazaki A; Sugiyama T; Sawanishi T; Miyamoto K
Jpn J Cancer Res; 1998 Feb; 89(2):228-33. PubMed ID: 9548452
[TBL] [Abstract][Full Text] [Related]
17. Effect of methylxanthine derivatives on doxorubicin transport and antitumor activity.
Kakuyama A; Sadzuka Y
Curr Drug Metab; 2001 Dec; 2(4):379-95. PubMed ID: 11766989
[TBL] [Abstract][Full Text] [Related]
18. Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect.
Kang W; Weiss M
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):151-5. PubMed ID: 12595956
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
20. 2-Deoxy-D-glucose enhances the anti-cancer effects of idarubicin on idarubicin-resistant P388 leukemia cells.
Matsuo T; Konya Y; Hirayama E; Sadzuka Y
Oncol Lett; 2020 Jul; 20(1):962-966. PubMed ID: 32566026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
